MedTrace Logo

Effectiveness of Community-based Approach in Reducing the Intimate Partner Violence (IPV) Exposure and Outcome

NCT06768502 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-01-10

No results posted yet for this study

Summary

Abstract

Background:

There is a little known about the effectiveness of Community-Based Approach (CBA) on reduction of intimate partner violence (IPV) exposure, anxiety, depression and PTSD symptoms as outcomes in collectivist and post-genocide societies like Rwanda. This study, therefore, aimed at assessing the effectiveness of Community-Based Approach (CBA) for IPV victimization and perpetration as well as it's associated mental health outcomes in Rwanda.

Methods:

This is a Randomized Controlled Trial (RCT) study which will be conducted using a sample of 31 couples (MA =36.9, SD=9.9), with 16 couples assigned in treatment group and 15 assigned in control group. Data has to be collected using the Hurt, Insult, Threaten and Screaming (HITS-7) to assess IPV exposure; the Hopkins Symptom Checklist for anxiety and depression (HSCL-25); and the PTSD checklist for DSM-5 (PCL-5). Data will be analyzed using Pearson correlation and mixed ANOVAs to evaluate the effect of CBA over IPV occurrence and mental health outcomes.

Key words:

IPV, community support, emotions management, anxiety, depression, PTSD, Rwanda

Conditions

  • Intimate Partner Violence (IPV)
  • Anxiety
  • Depression
  • Post-traumatic Stress Disorder (PTSD)

Interventions

OTHER

Community Based Approach (CBA)

The community-based approach on IPV and sexual violence is conceived as a dynamic process where community members willing to recover from life wounds induced by IPV and sexual violence agree to share their lived experiences in order to work on them accordingly and to support each other in this healing journey.

Sponsors & Collaborators

  • University of Rwanda

    lead OTHER

Principal Investigators

  • Vincent Sezibera, Professor · University of Rwanda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-18
Primary Completion
2020-03-03
Completion
2020-12-11

Countries

  • Rwanda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06768502 on ClinicalTrials.gov